2022/12/22 | PRODUCT
Sysmex Receives Manufacturing and Marketing Approval for an Assay Kit to Identify Amyloid Beta (Aβ) Accumulation in the Brain, a Cause of Alzheimer's Disease, Using a Small Amount of Blood
Measurement of Plasma Aβ Using Automated Immunoassay System HISCL™-5000/HISCL™-800
2022/10/03 | CORPORATE
Sysmex and JCR Pharmaceuticals Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy
Aiming for the Research & Development and Early Commercialization of Regenerative Medicine Products Using Stem Cells, etc.
2022/08/01 | CORPORATE
Pilot, Inc. Becomes Wholly-owned Sysmex Subsidiary Through the Acquisition of Outstanding Shares
Reinforcing Software Design and Development Capabilities
2022/06/10 | CORPORATE
Bayerische Hausbau and MATRIX lay the foundation stone for the new work campus FLOW in Hamburg
The new work campus FLOW in Hamburg is becoming a reality: The MATRIX Group and Bayerische Hausbau laid the foundation stone today together with anchor tenant Sysmex Europe and the Second Mayor Katharina Fegebank.
2022/05/27 | CORPORATE
The Ajinomoto Foundation, Sysmex, and NEC initiate a cross-industry co-creation project to improve maternal and child health and nutrition in the Republic of Ghana
Contributing to Universal “Nutrition” Health Coverage
2022/02/15 | CORPORATE
Sysmex Establishes Subsidiary in Saudi Arabia
Reinforcing Sales, Service, and Support Structures to Expand Business in a Growing Market
2022/01/18 | CORPORATE
Sysmex R&D Center Europe and “academist” begin collaborating in providing academic research funds in Europe
“academist” and Sysmex R&D Center Europe collaborate in exploring and granting academic research in Europe in the healthcare area at the European universities’ research labs. Scientific researchers can apply for the research funds through academist’s website.
2021/12/08 | CORPORATE
Discover the fighter in you – through our latest antimicrobial resistance (AMR) awareness campaign!
The 2021 #AMRfighter campaign to raise awareness of antimicrobial resistance shows us that making small changes can make a big difference to help mitigate the growing problem.
2021/10/15 | CORPORATE
Sysmex Europe wins awards in the programme ‘Excellence in learning 2021’ by Brandon Hall Group
Following the success in 2019, Sysmex Europe receives two bronze awards for ‘Best customer training program’ and ‘Best advance in creating a learning strategy’ by the Brandon Hall Group this year.
2021/06/07 | CORPORATE
Patient stratification and prognostic scores – the value of routine diagnostic parameters in supporting COVID-19 disease management
Identification of COVID-19-positive patients upon hospital admission usually relies on RT-PCR tests, however, clinicians can utilise diagnostic information to make decisions during the first examination of a patient as well. If risk factors are already known, this can be combined with laboratory tests to provide an informed initial evaluation.
2020/12/11 | CORPORATE
Sysmex EMEA’s first virtual congress, Sysmex Expo 2020 – a great success!
From 8-10 December, Sysmex EMEA hosted their first ever virtual congress.
2020/12/03 | PRODUCT
Sysmex Launches Surgical Robot Unit, hinotori™ Surgical Robot System
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announced today that it will launch the hinotori Surgical Robot System, a surgical robot unit, and the HF Series Instrument, a reusable active endotherapy device (collectively referred to as "hinotori" hereinafter; manufacturer: Medicaroid Corporation [HQ: Kobe, Japan; President: Kaoru Asano]) on December 4, 2020 for medical institutions in Japan.
2020/11/05 | CORPORATE
"Conquering the wave" – preparing for the second wave of COVID-19
Sysmex Global Webinar for COVID-19
2020/10/09 | CORPORATE
Sysmex Europe is celebrating 40 years of diagnostic advancement and growth
Sysmex Europe GmbH celebrates 40 years of business in EMEA and looks forward to continuing lighting the way with diagnostics.
2020/03/27 | PRODUCT
Sysmex Obtains First Marketing Approval in Japan for the Novel Coronavirus Nucleic Acid Detection Kits (RT-PCR Method)
Aiming for early introduction of test kits forin vitrodiagnostic medical devicesin medical institutions
-Japanese market only-
-Japanese market only-
2020/03/05 | CORPORATE
Sysmex Presents Academic Report Related to the Clinical Utility of RAS Gene Mutation Testing for Colorectal Cancer Using Liquid Biopsy
Details of Report on Clinical Utility of OncoBEAM™ RAS CRC Kit presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2020 (ASCO-GI 2020)
2020/02/10 | PRODUCT
Magseed® magnetic marker approved for any soft tissue and long-term implantation across Europe
Endomag has received an extended indication for the long-term use of the Magseed® magnetic marker in any soft tissue. The extended indication was approved after the Magseed® marker was found to be accurate and easy to place in the breast and the armpit in a number of clinical studies. CE certification widening follows the 510(k) clearance from the U.S. Food and Drug Administration (FDA), which was received for the same indication already in 2018.
2020/01/29 | CORPORATE
Sysmex Invests in Astrego Diagnostics with a View to Developing New Urinalysis Solutions for the Primary Care Business
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has reached an agreement to invest in Astrego Diagnostics AB (HQ: Uppsala, Sweden; CEO: Ove Öhman). Through this investment, Sysmex aims to help commercialize a rapid drug susceptibility test that Astrego is developing for urinary tract infections.
2020/01/14 | PRODUCT
Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland
Hitado GmbH (Hitado), a Sysmex point-of-care subsidiary, and SphingoTec GmbH (sphingotec) have signed an exclusive distribution agreement for the commercialisation of the Nexus IB10 diagnostic platform by Hitado in Germany. Further, Sysmex Suisse AG will commercialise the platform in Switzerland.
2020/01/14 | CORPORATE
Sysmex gives back – supporting social development together
Science and diagnostics are fascinating – at least that’s what we at Sysmex believe. When the opportunity comes along to fuel excitement for science together with other knowledge providers, we take it.
2019/12/20 | PRODUCT
OSNA for lung cancer – the newest addition to our oncology portfolio
OSNA, a molecular assay for accurate detection of lymph node metastases, is now available for lung cancer!
2019/12/02 | CORPORATE
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
2019/11/29 | CORPORATE
Sysmex Europe GmbH wins Silver Technology Award from the 2019 Learning In Practice Awards Program by Chief Learning Officer magazine.
Learning awards seem a little bit like in the movie industry – you may get one in one category, but there are always more categories where you can win!
2019/11/07 | CORPORATE
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31
Sysmex’s announced today the financial results of the first six months of the fiscal year ending March 31.
2019/11/05 | CORPORATE
Sysmex Wins Awards in 2019 Kinki Local Commendations for Innovations
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received a Minister of Education, Culture, Sports, Science and Technology Prize, and Encouragement Prizes for Inventions, at the Kinki* Local Commendation for Inventions, sponsored by the Japan Institute of Invention and Innovation.
2019/11/01 | CORPORATE
Sysmex and OPTiM Reach a Basic Agreement on the Establishment of a Joint Venture to Accelerate the Commercialization of Digital Medicine to Support Next-Generation Healthcare and Diagnostics
Aiming toward the Early-Stage Provision of Platforms and Applications Related to Digital Medicine
2019/10/30 | CORPORATE
Industry, Government and Academia Jointly Establish a General Incorporated Association to Promote the Bioresource Business
Jointly Established by Kobe University, the City of Kobe, the Foundation for Biomedical Research and Innovation at Kobe, and Sysmex
2019/10/02 | CORPORATE
Knowledge Is Power - Celebrating 10 Years of Sysmex Academy and More
Medical diagnostics company Sysmex Europe GmbH celebrates the 10th anniversary of the Sysmex Academy in October. Sysmex is the only company to have such a longstanding education system in place for both employees, distributors, and later on, end-customers.
2019/09/19 | PRODUCT
Sysmex Launches Caresphere™ QM, an Operational Support System for Testing Quality Management
Realizing the Operation of High-Quality Clinical Laboratories through our New Caresphere™ Solution
2019/09/17 | CORPORATE
Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Fourth Consecutive Year
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that it has been selected for inclusion in the Dow Jones Sustainability World Index (DJSI World), a leading global index of ESG investment, for the fourth consecutive year.
2019/09/06 | CORPORATE
Sysmex Europe GmbH wins the Silver Award for ‘Best Customer Training Program’ from the 2019 Brandon Hall Group Excellence in Learning Awards
The nomination was based on the customer learning portal – Sysmex Academy – that would supplement the face-to-face training with a broad selection of digital training media and live webinars.
2019/09/03 | CORPORATE
Japan’s First Automated Hematology Analyzer Registered by the National Museum of Nature and Science as “Essential Historical Material for Science and Technology”
-Using Unique Technology to Cultivate True Automation in Blood Cell Counting-
2019/08/29 | CORPORATE
Hamburg leaders visited Sysmex Corporation in Kobe
At the end of August, a delegation of high-ranking representatives, including Hamburg’s First Mayor Dr Peter Tschentscher, spent one day in Kobe as part of their tour of Japan and China.
2019/07/19 | PRODUCT
Liquid Biopsy performance comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS testing published in Scientific Reports (Nature Journal)
Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces publication of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, the OncoBEAM™ RAS CRC and the Idylla ctKRAS Mutation Test from the BioCartis Group NV.
2019/06/04 | PRODUCT
World Anti-Doping Agency Coordinates Global Implementation of Sysmex Analyzers at All Blood Laboratories
Contributing to Clean and Fair Sports Management by Enhancing the Quality of Doping Tests
2019/05/30 | PRODUCT
Sysmex Inostics OncoBEAM™-EGFR digital PCR liquid biopsy demonstrates two-fold higher detection of p.T790M mutations in 183 NSCLC patients in comparison study
Sysmex Inostics announces the publication of clinical research conducted as part of the CIRculating CANcer (CIRCAN) Program at the Lyon Cancer Institute (Lyon, France) comparing the performance of Sysmex Inostics BEAMing (beads, emulsion, amplification, and magnetics) assay for EGFR resistance mutations (OncoBEAM-EGFR) to a next-generation sequencing assay (56G Oncology Panel from Swift Biosciences) in non-small cell lung cancer (NSCLC) patients with EGFR sensitizing mutations under first-line tyrosine kinase inhibitor (TKI) therapy.
2019/05/28 | PRODUCT
Sysmex Inostics’ SafeSEQ ER+/HER2- breast cancer panel demonstrates equivalent sensitivity to OncoBEAM™ enhanced digital PCR technology for detection of mutations in circulating tumor DNA
Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast Cancer Research Consortium at the American Association of Cancer Research 2019 meeting in Atlanta, Georgia demonstrate how Sysmex Inostics’ novel SafeSEQ ER+/HER2- breast cancer panel can detect clinically relevant mutations in circulating tumor DNA (ctDNA) from patients with metastatic breast cancer with sensitivity equivalent to Sysmex’s highly clinically validated OncoBEAM liquid biopsy testing.
2019/05/08 | CORPORATE
Promoting Business Process Restructuring through Digitalization to Reinforce Corporate Foundations and Create New Value
To achieve business process restructuring, we will construct a digital foundation for the corporate management functions that underpin the Group management foundation, as well as for the value chain encompassing research and development, procurement and logistics, manufacturing, and sales and service.
2019/05/08 | CORPORATE
Sysmex Opens Technopark East Site, a Bio-Diagnostic Reagent Base
Strengthening Diagnostic Reagent Functions through an Integrated Structure from the Development of Substances to the Development, Production and Distribution of Bio-Diagnostic Reagents
2019/04/25 | PRODUCT
Sysmex Obtains CE Certification for Automated Hematology Analyzer XN-31, Which Has an Automatic Measurement Function for Red Blood Cells Infected by Malaria Parasites
Contributing to the Early Detection and Treatment of Malaria through Standardized and More Efficient Malaria Testing